Your browser doesn't support javascript.
loading
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure.
Zhu, Bing; You, Shaoli; Rong, Yihui; Yu, Qiang; Lv, Sa; Song, Fangjiao; Liu, Hongling; Wang, Huaming; Zhao, Jun; Li, Dongze; Liu, Wanshu; Xin, Shaojie.
Afiliação
  • Zhu B; Medical School of Chinese PLA, Beijing, China.
  • You S; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Rong Y; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Yu Q; Department of Infection and Liver Diseases, Peking University International Hospital, Beijing, China.
  • Lv S; Department of Interventional Therapy, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Song F; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Liu H; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Wang H; Liver Transplantation Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Zhao J; Department of Interventional Therapy, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Li D; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Liu W; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Xin S; Liver Failure Treatment and Research Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Braz J Med Biol Res ; 53(11): e9728, 2020.
Article em En | MEDLINE | ID: mdl-33053116
The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Insuficiência Hepática Crônica Agudizada / Hepatite B Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Braz J Med Biol Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Insuficiência Hepática Crônica Agudizada / Hepatite B Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Braz J Med Biol Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Brasil